首页 | 本学科首页   官方微博 | 高级检索  
     

应用分子靶向治疗的时机选择
引用本文:张凯,赵瑞景,陈连刚,朱铁年. 应用分子靶向治疗的时机选择[J]. 医学与哲学(人文社会医学版), 2014, 0(1): 46-48
作者姓名:张凯  赵瑞景  陈连刚  朱铁年
作者单位:[1]白求恩国际和平医院肿瘤科,河北石家庄050082 [2]河北医科大学,河北石家庄050017
基金项目:国家自然科学基金,项目编号:81071846;河北省自然科学基金,项目编号:H2013505059;河北省科技厅国际合作项目,项目编号:12396107D;吴阶平基金,项目编号:320.6750.12604
摘    要:分子靶向药物的出现显示出肿瘤治疗传统模式的重要进展。与传统放疗、化疗相比,分子靶向治疗因其特异性高、不良反应轻微,在恶性肿瘤个体化治疗中扮演重要角色。十五年来,分子靶向药物的出现,给肿瘤的治疗模式带来重大改变,也给临床医生带来新的挑战。准确把握分子靶向药物应用时机,获得最大临床效果,已成为肿瘤治疗领域关注热点。本文就非小细胞肺癌、消化系统肿瘤、乳腺癌、肾癌治疗中分子靶向药物如何选择应用时机进行阐述。

关 键 词:肿瘤分子靶向药物,非小细胞肺癌,乳腺癌,消化系统肿瘤,肾癌

Proper Timing of Apply Molecular-targeted Therapy
Affiliation:ZHANG Kai, ZHAO Rui-jing, CHEN Lian-gang, et al. (Department of Oncology, Bethune International Peace Hospital, Shijiazhuang 050082, China)
Abstract:The development of molecule-targeted therapy is a major breakthrough in the treatment of cancer. Compared with radiotherapy and chemotherapy, molecule-targeted therapy perform an important role in individually tailored cancer therapy because of the lower toxicity and higher efficiency. Over the recent 15 years, the emergence of molecule-targeted therapy has brought great change to treatment of cancer, and also brought challenges to clinician. The timing of using the molecular-targeted therapy has become a heatedly-discussed issue. This review illustrated the issue from the perspective of molecular targeted therapies which were recommended for the cure o[ non small cell lung cancer, breast cancer, malignancies in digestive system and kidney cancer.
Keywords:molecule-targeted drugs   non-small cell lung cancer   breast cancer   malignancies in digestive system   kidney cancer
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号